Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects. - Wikidata - awgldk - TriplyDB

Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.

Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.

http://www.wikidata.org/entity/Q37412777

about

Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.

http://www.wikidata.org/entity/Q37412777

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of Increased Gastric pH ...... acetrapib in Healthy Subjects.

@en

Impact of Increased Gastric pH ...... acetrapib in Healthy Subjects.

@nl

type

label

Impact of Increased Gastric pH ...... acetrapib in Healthy Subjects.

@en

Impact of Increased Gastric pH ...... acetrapib in Healthy Subjects.

@nl

prefLabel

Impact of Increased Gastric pH ...... acetrapib in Healthy Subjects.

@en

Impact of Increased Gastric pH ...... acetrapib in Healthy Subjects.

@nl

P1433

Q37412777-4375CBB4-9C8D-4A6A-8E8C-9B76130D8B6F

P1476

Q37412777-5AE28797-A19F-4993-B796-2495B583AE04

P2093

Q37412777-01DA07C9-2D50-4BA6-972F-F324718C41BC

Q37412777-0EFFEFAC-7564-427D-B37D-D83BFE54357A

Q37412777-277F1576-B277-4DEB-A043-079DF62B4512

Q37412777-4B16FB8E-3813-4B1C-8D0B-18EF79512C2D

Q37412777-51216E58-35A9-4DCB-8BF6-4238D74A4B27

Q37412777-784D4E1A-1EEE-41E7-925F-70A85AA2A113

Q37412777-E10D9A0E-9074-4C62-8938-FFC36705D5E2

P2860

Q37412777-551F574A-6D72-4824-80F4-E1878AF81D2E

Q37412777-5AE5DE26-D1FE-435D-960C-204D702D196F

Q37412777-5C1EB959-D0F4-45F6-935B-7BF5EAF1E78A

Q37412777-8446BA37-2804-4AD1-9DCB-926430AB0C9C

Q37412777-91B37E2E-D054-4F9F-8E1C-6A40C0AB15AD

Q37412777-A09E709D-6BDB-48B9-82FD-AE81A85604E0

Q37412777-A68BC76D-C684-4BA7-AFE1-2A955473F80D

Q37412777-CB4BC771-2BF4-4EED-89F2-A5EB5C8E215F

Q37412777-DB3B4B0A-ACED-4D30-90F4-6C63C4386EFC

Q37412777-F984ACF7-772F-4C78-8614-BEB591543C54

P304

Q37412777-B76E607A-6942-481B-9CE0-32AE638DFDB6

P31

Q37412777-38D86313-848D-45C8-A33A-77FBDD93DD53

P356

Q37412777-BFB6D624-E2D7-471B-A637-BF9B979F2998

P407

Q37412777-2C1A1A22-799A-462F-B997-C4782D6CB1BB

P433

Q37412777-33E9494E-C46C-4E22-B9A3-3980453362AE

P478

Q37412777-B16AABD2-8CA2-4961-89FE-D20D7AE8F83D

P577

Q37412777-0A5F7EEF-B51B-4A07-9775-C4314101DA5E

P698

Q37412777-533F76DD-39A5-4CF5-BC57-DDCFE98F18EC

P932

Q37412777-C9E7CA52-CA0F-490B-BD2F-0A6F87A53F44

P356

P1433

Pharmacotherapy

P1476

Impact of Increased Gastric pH ...... acetrapib in Healthy Subjects.

@en

P2093

Christine Hale

http://www.w3.org/2001/XMLSchema#string

David S Small

http://www.w3.org/2001/XMLSchema#string

Delyn Downs

http://www.w3.org/2001/XMLSchema#string

Ellen A Cannady

http://www.w3.org/2001/XMLSchema#string

Jane Royalty

http://www.w3.org/2001/XMLSchema#string

Jeffrey G Suico

http://www.w3.org/2001/XMLSchema#string

Ming-Dauh Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk.

Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.

Plasma cholesteryl ester transfer protein.

Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults

Rationale for cholesteryl ester transfer protein inhibition.

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors

P304

749-756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1778

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27284735

http://www.w3.org/2001/XMLSchema#string

P932

5108428

http://www.w3.org/2001/XMLSchema#string